Alto Neuroscience (NYSE:ANRO) Releases Earnings Results, Beats Estimates By $0.08 EPS

Alto Neuroscience (NYSE:ANRO) announced its earnings results on Wednesday. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08, FiscalAI reports.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $29.98 on Thursday. The company has a market capitalization of $1.05 billion, a PE ratio of -12.39 and a beta of 1.06. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. Alto Neuroscience has a 52-week low of $3.02 and a 52-week high of $31.83. The company has a 50-day simple moving average of $25.44 and a 200 day simple moving average of $22.57.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ANRO. Robert W. Baird cut their price objective on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Zacks Research lowered shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. Bank of America assumed coverage on Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Wall Street Zen lowered Alto Neuroscience from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.62.

Institutional Investors Weigh In On Alto Neuroscience

Large investors have recently modified their holdings of the stock. AQR Capital Management LLC bought a new position in Alto Neuroscience during the first quarter valued at $52,000. Invesco Ltd. bought a new stake in shares of Alto Neuroscience in the first quarter valued at approximately $67,000. Bridgeway Capital Management LLC lifted its stake in shares of Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after buying an additional 25,000 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in Alto Neuroscience in the 4th quarter worth approximately $198,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Alto Neuroscience in the fourth quarter worth $221,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.